the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of HCC.However,in 2020,the IMbrave150 trial demonstrated that combination therapy of atezolizumab(antiprogrammed death-ligand 1[PD-L1])and bevacizumab(anti-vascular ...
前段时间,美国食品和药物管理局(FDA)宣布批准抗PD-L1疗法阿特珠单抗Atezolizumab联合贝伐单抗Bevacizumab,用于治疗先前未接受过系统治疗的不可切除性或转移性肝细胞癌(HCC)患者。香港临床肿瘤科张文龙医生指出,来自IMbrave150临床试验的数据显示,与标准护理药物索拉非尼Sorafenib相比,该联合治疗显著延长了总生存期(OS)和无...
值得一提的是,Atezolizumab+Bevacizumab组合是第一个也是唯一一个被批准用于治疗不可切除性或转移性肝细胞癌的癌症免疫治疗方案。来自IMbrave150临床试验的数据显示,与标准护理药物索拉非尼(Sorafenib)相比,Atezolizumab+Bevacizumab联合治疗显著延长了总生存期(OS)和无进展生存期(PFS)。 IMbrave150是在最常见的肝癌治疗中显...
今年早些时候,IMbrave150(NCT03434379)研究的的患者入组已经完成,这是一项开放标签、多中心、随机III期研究,在先前未接受系统治疗的不可切除性肝细胞癌患者中开展,正在调查Atezolizumab与Bevacizumab联合治疗方案相对于多激酶抑制剂Sorafenib的疗效和安全性。该研究预计将在今年晚些时候公布结果。 研究人员为Atezolizumab制定了...
就在北京时间5月14日凌晨,一期国际杂志《NEJM(新英格兰杂志)》上公布了关于III期试验IMbrave150的完整数据,宣告PD-1抑制剂阿替利珠单抗(Atezolizumab)联合抗血管生成药贝伐珠单抗(Bevacizumab),能够成功地用于治疗既往未接受过系统性治疗的不可切除的肝细胞癌(HCC)患者。这意味着相对于标准治疗药物索拉非尼(Sorafenib),...
Could you discuss the IMbrave150 trial and how the combination of atezolizumab and bevacizumab has replaced sorafenib as the frontline standard of care? In the past, sorafenib used to be the only available first-line TKI. Then came the REFLECT study, which was also presented a couple of years...
2 The doublet also reduced the risk of disease progression or death by 41% compared with sorafenib (HR, 0.59; 95% CI, 0.47-0.76; P <.0001). “[Atezolizumab] in combination with [bevacizumab] is the first treatment to be approved in over a decade that has improved overall survival (OS...
Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. J Clin Oncol. 2021;39(15_suppl):...
the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of HCC.However,in 2020,the IMbrave150 trial demonstrated that combination therapy of atezolizumab(antiprogrammed death-ligand 1[PD-L1])and bevacizumab(anti-vascular ...
EMERALD-1: Durvalumab/Bevacizumab Plus TACE in Unresectable HCC Unpacking the EMERALD-1 Treatment Approach for HCC Gholam Explores the Phase 3 RATIONALE-301 Study of Sorafenib in HCC Discussing Treatment Options for Patients With HCC What Will Be the Next Frontline Therapy for HCC?